Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Annovis Bio, Inc.

Annovis to Host Year-End Investor Webcast on December 11, 2024
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
From Annovis Bio, Inc.
Via GlobeNewswire
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Reports Second Quarter Financial Results and Provides Business Update
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
From Annovis Bio, Inc.
Via GlobeNewswire
Annovis Bio Announces Pricing of $7.5 Million Public Offering
From Annovis Bio, Inc.
Via Business Wire
Tickers ANVS
Annovis Bio Announces Launch of Proposed Public Offering
From Annovis Bio, Inc.
Via Business Wire
Tickers ANVS
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
From Annovis Bio, Inc.
Via Business Wire
Tickers ANVS
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
From Annovis Bio, Inc.
Via Business Wire
Tickers ANVS
Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Annovis Bio, Inc.
Via Business Wire
Tickers ANVS
Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
From Annovis Bio, Inc.
Via Business Wire
Tickers ANVS
Annovis Bio Announces the Filing of a Groundbreaking Patent
From Annovis Bio, Inc.
Via Business Wire
Tickers ANVS
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
From Annovis Bio, Inc.
Via Business Wire
Tickers ANVS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.